EpiEndo Pharmaceuticals

Focus: EpiEndo Pharmaceuticals is a pre-revenue biotech focused on treatments for chronic respiratory illnesses, founded in 2023 and headquartered in Reykjavík, Iceland. The company is in early-stage development with a single lead asset (EP395) across multiple indications.

Neurology Respiratory

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About EpiEndo Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow EpiEndo Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

5 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

EP395

Chronic Obstructive Pulmonary Disease

Phase 1

Clinical Trials (1)

NCT05516316Clinical Trial Comparing the Pharmacological Effects of EP395 With Placebo in Healthy Adults

Phase 1

Help build intelligence for EpiEndo Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity at a newly founded company (2023) with potential to shape organizational culture and early pipeline strategy
Focus on high-unmet-need respiratory disease space (COPD exacerbation, chronic COPD) with strong clinical relevance
Multi-indication asset (EP395) demonstrates broad potential utility across respiratory, neurology, and oncology domains

Watch Out For

No active job openings currently listed, signaling early-stage hiring constraints or unfilled pipeline
Zero publications and limited public disclosure on scientific progress raises transparency and validation concerns
Pre-revenue status with undisclosed funding means extreme cash runway risk and high probability of restructuring before commercialization

Generated by Claude from EpiEndo Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

EP395

Chronic Obstructive Pulmonary Disease Exacerbation

Phase 1

Clinical Trials (1)

NCT06118684Clinical Trial to Assess Effect of Verapamil on Systemic Exposure of EP395 and Effect of EP395 on Systemic Exposure of Midazolam and Digoxin

Phase 1

EP395

Healthy Volunteer

Phase 1

Clinical Trials (1)

NCT06677918Clinical Trial Investigating the Effects of EP395 Following an Inhaled Endotoxin Challenge in Healthy Adults

Phase 1

EP395

Adult ALL

Phase 1

Clinical Trials (1)

NCT04819854Single and Multiple Ascending Dose Study With EP395